Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Recruiting

Phase 1

Phase 2

IbrutinibBruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT02315326

Conditions

Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)

Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ibrutinib

HD- Methotrexate (MTX)

Rituximab + HD- Methotrexate (MTX)

procarbazine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-14. This information was provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center on 2025-07-01.